ROCKVILLE, Md., June 24 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into an agreement with Chiltern International, Inc. for the activities of pharmacovigilence/safety reporting and medical information services for Western Europe.
James R. Miller, President & CEO of Pinnacle Biologics stated, "The completion of the Chiltern agreement represents a significant step in the process of offering a full range of services and solutions to the pharmaceutical/biotechnology companies that we currently represent or will partner with in the future. We are proud to be associated with Chiltern."
"Chiltern is extremely excited about expanding our service portfolio to meet the Pinnacle Biologics unique Pharmocovigilence, Safety and Medical Information requirements and help accelerate the commercialization of pharmaceutical products that are promoted and distributed by Pinnacle," noted Glenn Kerkhof, Chief Executive Officer of Chiltern
About Pinnacle Biologics
Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.
Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.
Pinnacle holds executive offices in Bannockburn, Illinois, satellite offices in Rockville, Maryland, and Almere, The Netherlands. Further information is available at http://www.pinnaclebiologics.com
Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing
international Phase I to Phase IV clinical trials across a broad range of
therapeutic areas for a wide variety of clients. Chiltern employs more than
1,200 people with 23 offices across the United States, Europe, Latin
America and in India. Chiltern provides services including Early Phase,
Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory
Affairs and Resourcing Solutions. Further information is available at
James R. Miller, Pinnacle
President & CEO
|SOURCE Pinnacle Biologics|
Copyright©2008 PR Newswire.
All rights reserved